IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer
- 31 January 2013
- journal article
- Published by Elsevier BV in Lung Cancer
- Vol. 79 (1), 83-90
- https://doi.org/10.1016/j.lungcan.2012.10.003
Abstract
No abstract availableThis publication has 47 references indexed in Scilit:
- Interleukin‐23 receptor polymorphism as a risk factor for oral cancer susceptibilityHead & Neck, 2011
- Interleukin-23: A key cytokine in inflammatory diseasesAnnals of Medicine, 2011
- The Role of Inflammation in the Pathogenesis of Non-small Cell Lung CancerJournal of Thoracic Oncology, 2010
- Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor MicroenvironmentCancer Cell, 2009
- The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17–producing effector T helper cells in vivoNature Immunology, 2009
- A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease GeneScience, 2006
- IL‐12 and IL‐23: master regulators of innate and adaptive immunityImmunological Reviews, 2004
- A unique role for IL-23 in promoting cellular immunityJournal of Leukocyte Biology, 2003
- A Receptor for the Heterodimeric Cytokine IL-23 Is Composed of IL-12Rβ1 and a Novel Cytokine Receptor Subunit, IL-23RThe Journal of Immunology, 2002
- Novel p19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from IL-12Immunity, 2000